REGENXBIO Inc. (RGNX) is scheduled to report additional interim data from its phase II AAVIATE trial, including full six-month results from Cohorts 5 and 6, at the Hawaiian Eye and Retina meeting today, i.e. January 16, 2024.
AAVIATE is a phase II trial of the company's lead gene therapy program ABBV-RGX-314 using suprachoroidal delivery for the treatment of wet AMD.
Wet AMD, a significant cause of vision loss in the United States, Europe and Japan, affects up to 2 million people in these geographies alone. It is characterized by new, leaky blood vessel formation in the retina.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.